Cargando…
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
Entrectinib (Rozlytrek(®)) is an orally active, CNS-penetrant, small-molecule, selective inhibitor of the tropomyosin receptor tyrosine kinases TRKA/B/C [encoded by the neurotrophic tyrosine receptor kinase (NTRK) genes NTRK1/2/3, respectively], the proto-oncogene tyrosine-protein kinase ROS1 (ROS1)...
Autor principal: | Frampton, James E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149347/ https://www.ncbi.nlm.nih.gov/pubmed/33871816 http://dx.doi.org/10.1007/s40265-021-01503-3 |
Ejemplares similares
-
Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021) -
Efmoroctocog Alfa: A Review in Haemophilia A
por: Frampton, James E.
Publicado: (2021) -
Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021) -
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020) -
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Frampton, James E.
Publicado: (2020)